The Prognostic Value of Cardiac Troponin in a Revascularized Cohort with First-Time Myocardial Infarction
2025
Authors
Earle, N., Poppe, K., Pilbrow, A., Logue, G., Rolleston, A., Wihongi, H., Henare, K., Lumley, T., Porter, G., Kerr, A., Devlin, G., Stewart, R., Cameron, V., Legget, M., Doughty, R.
Abstract
Introduction: The prognostic value of cardiac troponins in revascularized patients with myocardial infarction (MI) is uncertain. This study examined the relationship between peak troponin levels and adverse outcomes in a revascularized cohort from the Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS). Methods: MENZACS enrolled patients with a first-time acute coronary syndrome from 2015 to 2019. Peak high sensitivity troponin was standardized by dividing the observed peak troponin by the upper limit of normal. The primary outcome was a composite of all-cause death or cardiovascular readmission, determined through national datasets. Troponin’s relationship with outcomes was analysed using penalized spline Cox regression. Results: Among 1,645 revascularized patients (81% male, mean age 61, 74% European, 14% Māori, 5% Pacific, 5% Indian, 3% Other; 46% ST-elevation MI (STEMI), 54% non-STEMI), higher peak troponin was associated with male sex, STEMI, current smoking, and elevated N-terminal pro-B-type natriuretic peptide levels. Over a median of 4.9 years, 402 (24%) people experienced the primary outcome. Peak troponin levels were not significantly associated with this outcome. Conclusion: In this revascularized cohort surviving a first-time MI, the magnitude of peak troponin elevation was not associated with all-cause death or cardiovascular readmission.
Publication Link
